188 related articles for article (PubMed ID: 11719444)
21. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma.
Brown VL; Harwood CA; Crook T; Cronin JG; Kelsell DP; Proby CM
J Invest Dermatol; 2004 May; 122(5):1284-92. PubMed ID: 15140233
[TBL] [Abstract][Full Text] [Related]
22. Two cases of uveal amelanotic melanoma in transgenic Tyr-HRAS+ Ink4a/Arf heterozygous mice.
Latendresse JR; Muskhelishvili L; Warbritton A; Tolleson WH
Toxicol Pathol; 2007 Oct; 35(6):827-32. PubMed ID: 17987514
[TBL] [Abstract][Full Text] [Related]
23. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia.
Volanakis EJ; Boothby MR; Sherr CJ
Exp Hematol; 2013 Apr; 41(4):377-86. PubMed ID: 23178376
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
26. Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.
Kawada Y; Nakamura M; Ishida E; Shimada K; Oosterwijk E; Uemura H; Hirao Y; Chul KS; Konishi N
Jpn J Cancer Res; 2001 Dec; 92(12):1293-9. PubMed ID: 11749694
[TBL] [Abstract][Full Text] [Related]
27. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
29. p16(Ink4a) interferes with Abelson virus transformation by enhancing apoptosis.
Sachs Z; Sharpless NE; DePinho RA; Rosenberg N
J Virol; 2004 Apr; 78(7):3304-11. PubMed ID: 15016851
[TBL] [Abstract][Full Text] [Related]
30. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
31. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.
Hearle N; Damato BE; Humphreys J; Wixey J; Green H; Stone J; Easton DF; Houlston RS
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):458-62. PubMed ID: 12556369
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages.
Randle DH; Zindy F; Sherr CJ; Roussel MF
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9654-9. PubMed ID: 11481442
[TBL] [Abstract][Full Text] [Related]
33. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines.
Park YB; Park MJ; Kimura K; Shimizu K; Lee SH; Yokota J
Cancer Genet Cytogenet; 2002 Mar; 133(2):105-11. PubMed ID: 11943335
[TBL] [Abstract][Full Text] [Related]
34. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model.
Ackermann J; Beermann F
Pigment Cell Res; 2005 Aug; 18(4):315-9. PubMed ID: 16029424
[TBL] [Abstract][Full Text] [Related]
35. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
36. Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status.
Xiong J; Epstein RJ
Mol Cancer Ther; 2009 Apr; 8(4):779-85. PubMed ID: 19372550
[TBL] [Abstract][Full Text] [Related]
37. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.
You MJ; Castrillon DH; Bastian BC; O'Hagan RC; Bosenberg MW; Parsons R; Chin L; DePinho RA
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1455-60. PubMed ID: 11818530
[TBL] [Abstract][Full Text] [Related]
38. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.
Chin L; Pomerantz J; Polsky D; Jacobson M; Cohen C; Cordon-Cardo C; Horner JW; DePinho RA
Genes Dev; 1997 Nov; 11(21):2822-34. PubMed ID: 9353252
[TBL] [Abstract][Full Text] [Related]
39. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus.
Gilley J; Fried M
Oncogene; 2001 Nov; 20(50):7447-52. PubMed ID: 11704876
[TBL] [Abstract][Full Text] [Related]
40. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice.
Shank-Calvo JA; Draheim K; Bhasin M; Kelliher MA
Oncogene; 2006 May; 25(21):3023-31. PubMed ID: 16407836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
